(MKGI) Booking Technology Unlocks Specialty Lodging Inventory

New-to-Market Timeshare and Resort Properties Now Available for Vacation Rental

(CBAY) Analyst Coverage Initiated

NEWARK, CA / April 25, 2016 / CymaBay Therapeutics Inc. (NASDAQ: CBAY) a biopharmaceutical company focused on developing therapies to treat metabolic diseases, including serious rare and orphan disorders, recently provided corporate highlights and announced financial results for the quarter and year ended December 31, 2015. “We have made significant progress during the last quarter in advancing the development of our two key clinical assets,” said Harold Van Wart, President and Chief Executive Officer of CymaBay. “Earlier in March, we reported some encouraging top-line data from our pilot Phase 2 study in patients with homozygous familial hypercholesterolemia. Analysis of the data showed that MBX-8025 demonstrated the ability to lower LDL-Cholesterol in a majority of patients, despite raising PCSK9 levels. We are evaluating the feasibility of conducting a second pilot study in combination with a PCSK9 inhibitor to assess whether the reductions in LDL-C can be amplified by neutralizing PCSK9.”

With the recent rally slowing down, what does the future hold for CBAY?

For a more detailed research report with analyst comments on CymaBay Therapeutics Inc. (NASDAQ: CBAY) please follow the link. There is no cost obligation required to view analyst brief: http://broadstreetalerts.com/cymabay-therapeutics-inc/.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Broad Street Alerts this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. The subject Company has not compensated Broad Street Alerts or Robert Borowski for the creation or dissemination of this report. Broad Street Alerts is the party responsible for issuing the press release and for hosting the full analyst report on Broad Street Alerts website. Robert Borowski is the author of research report. This information is submitted to increase awareness for the Broad Street Alerts brand to the investing public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@broadstreetalerts.com. For any urgent concerns or inquiries, please contact us at admin@broadstreetalerts.com.

NOT FINANCIAL ADVICE

Broad Street Alerts makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Broad Street Alerts is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming Broad Street Alerts has compensated Robert Borowski, up to two hundred fifty dollars for the distribution rights to disseminate analyst report. No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

(CDOR) Announces Sale of Non-Core Super 8

(EXEL) Announces FDA Approval of CABOMETYX™

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX™ (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. RCC is the most common form of kidney cancer in adults. CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters — overall survival, progression-free survival and objective response rate.

“With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer while also delaying the progression of their cancer,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “We are proud to bring new hope to this community, who are looking for more therapies that can help extend lives. Exelixis is committed to making CABOMETYX available to patients in need within the next couple weeks.”

“The efficacy profile demonstrated by CABOMETYX in the METEOR trial, now complemented by the overall survival benefit, is highly compelling,” said Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. “CABOMETYX is distinct from other approved treatment options, as it targets multiple tyrosine kinases involved in the development of RCC, including MET, AXL and three VEGF receptors. At the same time, physicians are very familiar with this class of drug and how to use dose adjustments to balance safety and efficacy. The approval of CABOMETYX is wonderful news for physicians who are looking for a new option for their previously treated patients with advanced kidney cancer.”

The approval of CABOMETYX is based on results of the phase 3 METEOR trial, which met its primary endpoint of improving progression-free survival. Compared with everolimus, a standard of care therapy for second-line RCC, CABOMETYX was associated with a 42 percent reduction in the rate of disease progression or death. Median progression-free survival for cabozantinib was 7.4 months versus 3.8 months for everolimus (HR=0.58, 95% CI 0.45-0.74, P<0.0001). CABOMETYX also significantly improved the objective response rate compared with everolimus. These data were presented at the European Cancer Congress in September 2015 and published in The New England Journal of Medicine.

As announced in February 2016, CABOMETYX also demonstrated a statistically significant and clinically meaningful increase in overall survival in the METEOR trial. Compared with everolimus, CABOMETYX was associated with a 34 percent reduction in the rate of death. Median overall survival was 21.4 months for patients receiving CABOMETYX versus 16.5 months for those receiving everolimus (HR=0.66, 95% CI 0.53-0.83, P=0.0003).

The most common (frequency ≥25 percent) adverse reactions in CABOMETYX-treated patients include diarrhea, fatigue, nausea, decreased appetite, hand-foot syndrome, high blood pressure, vomiting, weight loss, and constipation. Dose reduction rates were 60 percent for CABOMETYX and 24 percent for everolimus. The rate of treatment discontinuation due to adverse reactions was low (10 percent in each arm) and consistent with that previously reported for everolimus.

Please see Important Safety Information below and full U.S. prescribing information at https://HCP.cabometyx.com/downloads/cabometyxuspi.pdf

Conference Call/Webcast at 4:00 EDT / 1:00 PDT Today

Exelixis management will discuss the CABOMETYX U.S. regulatory approval during a conference call beginning at 4:00 p.m. EDT/1:00 p.m. PDT today, April 25, 2016. To listen to a live webcast of the conference call, visit the Event Calendar page under Investors & Media at www.exelixis.com. Alternatively, participants may dial (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 94229895 to join by phone.

An archived replay of the webcast will be available on the Event Calendar page under Investors & Media at www.exelixis.com for one year. An audio-only phone replay will be available until 11:59 p.m. EDT on April 27, 2016. Access numbers for the phone replay are: (855) 859-2056 (domestic) and (404) 537-3406 (international); the passcode is 94229895.

About the METEOR Phase 3 Pivotal Trial

METEOR was an open-label, event-driven trial of 658 patients with advanced renal cell carcinoma who had failed at least one prior vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) therapy. The primary endpoint was progression-free survival. Secondary endpoints included overall survival and objective response rate. The trial was conducted at approximately 200 sites in 26 countries, and enrollment was weighted toward Western Europe, North America, and Australia.

Patients were randomized 1:1 to receive 60 mg of CABOMETYX daily or 10 mg of everolimus daily and were stratified based on the number of prior VEGF receptor TKI therapies received and on MSKCC risk criteria. No cross-over was allowed between the study arms.

About Advanced Renal Cell Carcinoma

The American Cancer Society’s 2016 statistics cite kidney cancer as among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S.¹ Clear cell RCC is the most common type of kidney cancer in adults.² If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 12 percent, with no identified cure for the disease.¹ Approximately 17,000 patients in the U.S. and 37,000 globally require second-line or later treatment.³

The majority of clear cell RCC tumors have lower than normal levels or function of the von Hippel-Lindau protein, which leads to higher levels of MET, AXL and VEGF.^4,5 Higher than normal levels of these proteins can promote tumor angiogenesis (blood vessel growth), growth, invasiveness and metastasis.^6-9 MET and AXL may also provide escape pathways that drive resistance to VEGF receptor inhibitors.^5,6

About CABOMETYX

CABOMETYX targets include MET, AXL and VEGFR-1, -2 and -3. In preclinical models, cabozantinib has been shown to inhibit the activity of these receptors, which are involved in normal cellular function and pathologic processes such as tumor angiogenesis, invasiveness, metastasis and drug resistance.

CABOMETYX, the tablet formulation of cabozantinib, will be available in 20 mg, 40 mg or 60 mg doses. The recommended dose is 60 mg orally, once daily.

On January 28, 2016, the European Medicines Agency (EMA) validated Exelixis’ Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy. The MAA has been granted accelerated assessment, making it eligible for a 150-day review, versus the standard 210 days. On February 29, 2016, Exelixis and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib indications outside of the United States, Canada and Japan.

Important Safety Information

Hemorrhage: Severe hemorrhage occurred with CABOMETYX. The incidence of Grade ≥3 hemorrhagic events was 2.1% in CABOMETYX-treated patients and 1.6% in everolimus-treated patients. Fatal hemorrhages also occurred in the cabozantinib clinical program. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.

Gastrointestinal (GI) Perforations and Fistulas: Fistulas were reported in 1.2% (including 0.6% anal fistula) of CABOMETYX-treated patients and 0% of everolimus-treated patients. GI perforations were reported in 0.9% of CABOMETYX-treated patients and 0.6% of everolimus-treated patients. Fatal perforations occurred in the cabozantinib clinical program. Monitor patients for symptoms of fistulas and perforations. Discontinue CABOMETYX in patients who experience a fistula that cannot be appropriately managed or a GI perforation.

Thrombotic Events: CABOMETYX treatment results in an increased incidence of thrombotic events. Venous thromboembolism was reported in 7.3% of CABOMETYX-treated patients and 2.5% of everolimus-treated patients. Pulmonary embolism occurred in 3.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients. Events of arterial thromboembolism were reported in 0.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients. Fatal thrombotic events occurred in the cabozantinib clinical program. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.

Hypertension and Hypertensive Crisis: CABOMETYX treatment results in an increased incidence of treatment-emergent hypertension. Hypertension was reported in 37% (15% Grade ≥3) of CABOMETYX-treated patients and 7.1% (3.1% Grade ≥3) of everolimus-treated patients. Monitor blood pressure prior to initiation and regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy. Discontinue CABOMETYX if there is evidence of hypertensive crisis or severe hypertension despite optimal medical management.

Diarrhea: Diarrhea occurred in 74% of patients treated with CABOMETYX and in 28% of patients treated with everolimus. Grade 3 diarrhea occurred in 11% of CABOMETYX-treated patients and in 2% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal treatments until improvement to Grade 1; resume CABOMETYX at a reduced dose. Dose modification due to diarrhea occurred in 26% of patients.

Palmar-Plantar Erythrodysesthesia Syndrome (PPES): Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 42% of patients treated with CABOMETYX and in 6% of patients treated with everolimus. Grade 3 PPES occurred in 8.2% of CABOMETYX-treated patients and in <1% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 PPES or Grade 3 PPES until improvement to Grade 1; resume CABOMETYX at a reduced dose. Dose modification due to PPES occurred in 16% of patients.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib clinical program. Perform an evaluation for RPLS in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Embryo-fetal Toxicity: CABOMETYX can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose.

Adverse Reactions: The most commonly reported (≥25%) adverse reactions are: diarrhea, fatigue, nausea, decreased appetite, PPES, hypertension, vomiting, weight decreased, and constipation.

Drug Interactions: Strong CYP3A4 inhibitors and inducers: Reduce the dosage of CABOMETYX if concomitant use with strong CYP3A4 inhibitors cannot be avoided. Increase the dosage of CABOMETYX if concomitant use with strong CYP3A4 inducers cannot be avoided.

Lactation: Advise a lactating woman not to breastfeed during treatment with CABOMETYX and for 4 months after the final dose.

Reproductive Potential: Contraception―Advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the final dose. Infertility ―CABOMETYX may impair fertility in females and males of reproductive potential.

Hepatic Impairment: Reduce the CABOMETYX dose in patients with mild (Child-Pugh score [C-P] A) or moderate (C-P B) hepatic impairment. CABOMETYX is not recommended for use in patients with severe hepatic impairment.

Please see full Prescribing Information at https://HCP.cabometyx.com/downloads/cabometyxuspi.pdf.

About Exelixis

Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer. Since its founding in 1994, three medicines discovered at Exelixis have progressed through clinical development to receive regulatory approval. Currently, Exelixis is focused on advancing cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors, which has shown clinical anti-tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. Two separate formulations of cabozantinib have received regulatory approval to treat certain forms of kidney and thyroid cancer and are marketed for those purposes as CABOMETYX™ tablets (U.S.) and COMETRIQ® capsules (U.S. and EU), respectively. Another Exelixis-discovered compound, COTELLIC™ (cobimetinib), a selective inhibitor of MEK, has been approved in major territories including the United States and European Union, and is being evaluated for further potential indications by Roche and Genentech (a member of the Roche Group) under a collaboration with Exelixis. For more information on Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of CABOMETYX; Exelixis’ commitment to making CABOMETYX available to patients within the next couple weeks and the doses in which CABOMETYX will be available; the eligibility for an expedited review of Exelixis’ MAA for cabozantinib in advanced RCC by the EMA; Exelixis’ commitment to developing small molecule therapies for the treatment of cancer; and Exelixis’ primary focus on the development and commercialization of cabozantinib. Words such as “committed,” “will,” “eligible,” “focusing,” or other similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX and the availability of coverage and reimbursement for CABOMETYX; Exelixis’ ability to judge the proper size and level of experience of the commercialization teams required to support the launch of cabozantinib for advanced RCC in the U.S.; Exelixis’ dependence on third-party vendors; risks and uncertainties related to regulatory review and approval processes and Exelixis’ compliance with applicable legal and regulatory requirements; Exelixis’ ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion; and other factors discussed under the caption “Risk Factors” in Exelixis’ annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2016, and in Exelixis’ other filings with the SEC. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

References

1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016.

2. Jonasch E., Gao J., Rathmell W.K., Renal cell carcinoma. BMJ. 2014; 349:g4797.

3. Decision Resources Report: Renal Cell Carcinoma. October 2014 (internal data on file).

4. Harshman, L.C. and Choueiri, T.K., Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 2013; 19(4):316-23.

5. Rankin et al., Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014; 111(37):13373-8.

6. Zhou L, Liu X-D, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2015 Sep 14. doi:10.1038/onc.2015.343. [Epub ahead of print].

7. Koochekpour et al.,The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999; 19(9):5902–5912.

8. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54:4233-4237.

9. Nakagawa M, Emoto A, Hanada T, Nasu N, Nomura Y. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma. Br J Urol. 1997;79:681-687.

Investors:
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations & Corporate Communications
shubbard@exelixis.com
or
Media:
Exelixis, Inc.
Lindsay Treadway, 650-837-7522
Corporate Communications
ltreadway@exelixis.com
or
For Exelixis, Inc.
Madeleine Shin, 212-546-7806
mshin@dna-comms.com

(PETX) & (LLY) Division Announce Global Strategic Collaboration

Agreement to expand Elanco’s companion animal portfolio, extend global reach of GALLIPRANT® (grapiprant tablets) in canine osteoarthritis therapy

GREENFIELD, Ind. and LEAWOOD, Kan., April 25, 2016  — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana’s Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.

“This deal expands Elanco’s robust companion animal portfolio, which will now give our customers and their patients a spectrum of treatments for managing osteoarthritic pain,” said Jeff Simmons, president of Elanco Animal Health.”At Elanco, we understand the powerful role healthy animals play in making life better. As pets become important parts of our families, the need to help them live longer, healthier, higher quality lives increases as well.”

The most common type of arthritis in dogs, osteoarthritis affects up to 20 percent of the adult canine population.¹ Osteoarthritis can result when joint cartilage – the protective material that cushions and allows smooth movement in a joint – becomes thin and breaks down over time, leading to pain and inflammation in the joint. The frequent result is stiffness and a reluctance to run, jump, or even climb steps.

“Aratana understands the value of relationships with the right collaborators,” said Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. “We believe that this collaboration with Elanco, a leading animal health company, is a watershed event for the emerging pet biotech sector and further validates our focus on the pet therapeutics opportunity.”

Under the terms of the agreement, Aratana will receive an upfront payment of $45 million, additional payments upon achievement of certain development, regulatory and sales milestones up to $83 million, and co-promotion fees and royalty payments.

Contacts:
For Elanco inquires:
Keri McGrath Happe
Communications Manager
Elanco Animal Health
T: +1-317-370-8394
E: mcgrath_happeks@elanco.com

For Aratana inquires:
Craig Tooman
Aratana Therapeutics, Inc.
ctooman@aratana.com
(913) 353-1026

Important Safety Information
GALLIPRANT^® (grapiprant tablets) is for use in dogs only. Do not use in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, or in pregnant or lactating dogs. Adverse reactions in dogs may include mild gastrointestinal effects including, vomiting, diarrhea and decreased appetite. Should not be used in dogs that have a hypersensitivity to grapiprant. If used long term, appropriate monitoring is recommended. Avoid use with COX-inhibiting NSAIDs or corticosteroids. Please see the full Prescribing Information.

ABOUT ELANCO
Elanco, a division of Eli Lilly and Company, provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. With a global presence of approximately 7,000 people and offices in more than 40 countries, Elanco anticipates, serves and supports the diverse and evolving needs of its customers–from veterinarians to food producers to all those concerned with animal health–to help them address the challenges of a diverse and changing world. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Additional information about Elanco is available at www.elanco.com, or follow us @Elanco.

ABOUT ARATANA THERAPEUTICS
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative pharmaceutical products for dogs and cats. Aratana believes that it can leverage the investment in the human pharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company has multiple products approved by the Food and Drug Administration’s Center for Veterinary Medicine or licensed by the United States Department of Agriculture. The Company’s pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious, unmet or underserved medical needs. Aratana believes providing innovative options to veterinarians and pet owners will help manage pets’ medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the collaboration between Aratana and Elanco, and reflects Lilly, Elanco’s and Aratana’s current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that the research collaboration will yield successful results, that either company will achieve the anticipated benefits or that the results will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s and Aratana’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission, respectively. Except as required by law, Elanco and Aratana undertakes no duty to update forward-looking statements to reflect events after the date of this release.

¹ JAVMA, Vol 236, No. 1, January 1, 2010 p 59-66

(BLDP) Protonex Subsidiary Demonstrates UAV Propulsion System with Boeing Insitu

VANCOUVER and SOUTHBOROUGH, MA, April 25, 2016  – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) announced that the company’s subsidiary, Protonex, has delivered prototype PEM (proton exchange membrane) fuel cell propulsion modules to Insitu, a wholly owned subsidiary of The Boeing Company, for use in its ScanEagle unmanned aerial vehicle (UAV). The ScanEagle platform has logged over 800,000 flight hours in military and civilian applications, making it one of the most successful UAV platforms to date.

Paul Osenar, President of Protonex said, “Fuel cell-powered systems offer compelling value for unmanned aerial vehicles due to improved reliability over small internal combustion engines, as well as very low heat and noise signatures. We believe that fuel cell systems have an extraordinary opportunity to play a key role in the propulsion of many unmanned systems. Our work with Insitu on the ScanEagle is an excellent example of the potential for fuel cells.”

Insitu’s ScanEagle is a versatile platform with multiple payload capabilities, including providing high-definition imaging at a fraction of the cost of larger UAV systems. The ScanEagle is operated in conjunction with Insitu’s Mark4 Launcher – a low-maintenance, runway-independent platform – along with its SkyHook^® recovery system.

ScanEagle is 1.55 meters (5.1 feet) in length, has a wingspan of 3.11 meters (10.2 feet) and maximum takeoff weight of 22 kilograms (48.5 lbs). The ScanEagle can fly at a maximum speed of 41.2 meters per second (80 knots), reach a ceiling of 5,944 meters (19,500 feet) and has an endurance capability of more than 24-hours. Additional details and images are available at http://www.insitu.com/information-delivery/unmanned-systems/scaneagle.

Use of the Protonex fuel cell propulsion modules are expected to provide a number of advantages over traditional internal combustion engine propulsion systems, including: significant improvement in the expected MTBF (mean time between failures) of up to 5x; silent operation; 100% throttle flexibility, including mid-air start-stop capability; and use of existing JP8 fuel in ground refueling systems.

Work related to the integration of the Protonex fuel cell propulsion module into the ScanEagle system is ongoing, with flight demonstrations planned for the second half of 2016.

About Ballard Power Systems
Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) provides clean energy products that reduce customer costs and risks, and helps customers solve difficult technical and business challenges in power and energy. To learn more about Ballard, please visit www.ballard.com.

This release contains forward-looking statements concerning anticipated product performance, customer benefits and market demand for our products. These forward-looking statements reflect Ballard’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard’s assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.

These statements involve risks and uncertainties that may cause Ballard’s actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard’s future performance, please refer to Ballard’s most recent Annual Information Form. Readers should not place undue reliance on Ballard’s forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward looking statements, other than as required under applicable legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.  The Ballard Common Shares have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

(SEED) Names New President & CEO

Board of Directors appoints Dr. William S. Niebur to grow business, lead strategic entry into global market

BEIJING, April 25, 2016  — The Board of Directors of Origin Agritech Ltd., a technology-focused crop seed provider, today announced Dr. William S. Niebur as the company’s new president and CEO. Dr. Niebur assumes the title from current CEO Dr. Gengchen Han, who will retain his position as Chairman of the Board.

Dr. Niebur takes the reins of the company at a time when Origin is strategically positioning itself as a global participant in the biotechnology and seed market. Origin will continue to enhance and expand its core seed business, while pursuing new opportunities and markets.

“This announcement is the next step in our strategic plan to grow our worldwide presence in the biotechnology and seed industries,” Dr. Han said. “Dr. Niebur’s extensive experience, strategic vision, industry relationships and reputation – in Asia, North and South America and Europe – will help to further accelerate Origin’s emergence on the global stage.”

“I am honored to be selected as the next president and CEO of Origin,” Dr. Niebur said. “This is a bold and innovative company that is redefining its future. Origin is well-positioned with its established core seed business and proprietary germplasm development program, as well as its emerging seed-traits business. Origin will continue to focus on growth while driving stronger execution in the Asia seed business. The recruitment of stronger talent, development and out-licensing of novel value-added traits, and deepening of current and new strategic partnerships to grow our business globally will become a significant part of Origin’s future.”

Dr. Niebur most recently served with DuPont Pioneer as Vice President and General Manager with strategic oversight responsibility for China, East Asia and Oceania. Dr. Niebur has been in the seed business for more than three decades, beginning his career as a corn geneticist in Princeton, Ill. He went on to gain extensive global experience, first overseeing research and development while living in Europe, then returning to North America as the company’s global Vice President for R&D, and finally moving into business operations managing seed businesses in East and North Asia. In 2015, Dr. Niebur was named as one of 50 people “Shaping the Future of the U.S.-China Relationship” in the Pacific Power Index, publicized by Foreign Policy Group. Dr. Niebur was instrumental in integrating technologies into plant genetics programs and was granted several patents which led to the commercialization of more than 30 branded products during his scientific career. Dr. Niebur holds both his Bachelor of Science and Master of Science degrees from Iowa State University. He earned his doctorate in plant breeding and cytogenetics from the University of Minnesota.

“I am proud of the work that has been accomplished by the research and business teams over the past 33 years, and humbled by the learning opportunities that were afforded to me in my career,” Dr. Niebur said. “After my retirement earlier this year, now seemed the right time for a new direction and challenge. I couldn’t be more excited about the opportunity to become the leader of a proven and established seed and technology company, which is strategically positioned for growth under the Chairmanship and future vision of Dr. Han, the Board of Directors and a new senior management team.”

Today’s announcement comes a little more than two weeks after Origin announced a major commercial collaboration agreement to develop new seed technologies for Chinese farmers in partnership with a leading multinational company. These combined efforts will contribute to the modernization and stabilization of China’s dynamic agriculture system, leading to improved food and environmental security, closely aligned with published government priorities and initiatives.

Origin has also applied for patents and regulatory approval in other countries, including the United States, to advance its global strategy to meet the needs of farmers around the world.

Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please visit the Company’s website at: http://www.originseed.com.cn or http://www.originseed.com.cn/en/.

Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company’s intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

CONTACT

Song Xu
song.xu@originseed.com.cn
+86 10 5890-7556

Eileen Wixted
ewixted@thinkwixted.com
(515) 226-0818

(ABUS) Presents Data from Combination Activity Studies of HBV Drug Candidates

Additional Preclinical Combination Data to be Presented This Year
Clinical Combination Studies to Begin in 2017

VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 22, 2016  — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentations this week by Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, on results of several preclinical HBV drug combination studies at the 29^th International Conference on Antiviral Research held April 17-21, and Cambridge Healthtech Institute’s 11^th Annual Drug Discovery Chemistry conference held April 19-22, 2016, both in San Diego.

“We are excited to present this intriguing data from our preclinical drug combination studies. These data show additive or synergistic activity in in vitro and in vivo studies that evaluate different HBV disease markers such as cccDNA synthesis and expression, HBV rcDNA synthesis, HBsAg production and serum HBV DNA. We believe that combination therapy will enable an HBV cure with a finite treatment duration, and we have built a diverse pipeline of HBV product candidates at Arbutus to support this strategy,” said Dr. Sofia. “Our thorough preclinical evaluation of combinations of HBV candidates with different direct acting anti-viral mechanisms of action will inform our proprietary clinical combination studies, which will begin in 2017.”

These initial preclinical combination studies have established the following:

• Our drug candidates ARB-1467, AB-423, and AB-199 are potent and selective inhibitors of their respective targets.
• These drug candidates can be used in combination with the ‘nuc’ standard of care without any antagonism of drug activity.
• These drug candidates when used in combination with the ‘nuc’ standard of care demonstrate at least additive and in some cases synergistic activity.
• That our first proprietary drug combination, RNAi plus capsid formation inhibitor, also demonstrates additive activity.
• These results support Arbutus’ combination strategy.

Summary of the Studies Presented:

The presentation can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations.

About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.  Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about using a combination therapy to enable an HBV cure with a finite treatment duration; beginning proprietary clinical combination studies in 2017; the effectiveness of HBV candidates; and developing and commercializing a cure for patients suffering from chronic HBV infection using a three-pillar strategy.

With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical and clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K and Arbutus’ continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com

Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com

Media
Please direct all media inquiries to: media@arbutusbio.com

(AGTC) Data Evaluating Novel AAV-Based Gene Therapy for LCA

Study results show that experimental gene therapy intervention improved several measures of visual function in majority of patients tested

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 22, 2016 – Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating an experimental recombinant AAV vector gene delivery in patients with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD), two related retinal diseases caused by mutations in the RPE65 gene that cause severe loss of vision in infancy. Results from the study, entitled “Results at 2 Years after Gene Therapy for RPE65-deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy,” were published online in the peer-reviewed journal Ophthalmology and will appear in the April print issue of the journal.

“LCA and SECORD are serious retinal degenerative conditions with no current treatments that can lead to total blindness and significantly impair quality of life in affected individuals,” said contributing study author Jeff Chulay, M.D., DTM&H, Vice President and Chief Medical Officer of AGTC. “We are encouraged by these results demonstrating that administration of a novel AAV-based gene therapy can improve several measures of abnormal visual function in patients affected by these disorders.”

The study was conducted at Oregon Health and Science University (OHSU) Casey Eye Institute (CEI) and University of Massachusetts.  The study enrolled eight adults and four children with LCA or SECORD who received a subretinal injection of a recombinant AAV expressing RPE65 (rAAV2-CB-hRPE65) at one of two dose levels in the poorer seeing eye. All subjects then underwent serial assessments of visual function and adverse events during two-year clinical follow-up to evaluate safety and efficacy parameters.

All subjects tolerated the surgery and study agent administration with no treatment-related serious adverse events reported. In the treated eye, best-corrected visual acuity (BCVA) increased in five subjects, static perimetry hill of vision measurements for the central 30° of the visual field increased in six subjects, total visual field hill of vision measurements increased in five subjects, and kinetic visual field area improved in three subjects. One study participant had a decrease in BCVA and two subjects had a decrease in kinetic visual field area. Common adverse events associated with the injection included subconjunctival hemorrhage in eight subjects and ocular hyperemia (redness) in five subjects. The investigators concluded that the treatment with rAAV2-CB-hRPE65 was not associated with serious adverse events and improvement in one or more measures of visual function was observed in 9 of 12 (75 percent) subjects.

“While AGTC has made a strategic decision to focus on commercializing treatments for other orphan indications, these results are promising and add to previously published proof of concept data supporting gene therapy applications for inherited retinal diseases,” noted Sue Washer, President and CEO of AGTC. “We have recently achieved several important clinical and regulatory milestones for the product candidates in our pipeline, including our lead product candidates for the treatment of the orphan indications X-linked retinoschisis and achromatopsia, and look forward to announcing continued progress in our primary clinical programs in the coming months.”

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC’s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function, and which currently lack effective medical treatments.

AGTC’s product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and early research studies in additional indications.  AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.

Forward Looking Statements
This release contains forward-looking statements that reflect AGTC’s plans, estimates, assumptions and beliefs. These statements relate to a variety of matters, including but not limited to, the anticipated progress of AGTC’s clinical and pre-clinical programs and the anticipated utility of AAV vectors made using AGTC’s proprietary manufacturing method and progress of or financial implications of AGTC’s various partnership activities. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors, which include, but are not limited to, the following: no gene therapy products have been approved in the United States and AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate; AGTC relies on third parties to conduct, supervise and monitor its clinical trials and to conduct certain aspects of its product manufacturing and protocol development; and increased regulatory scrutiny of gene therapy and genetic research could damage public perception of AGTC’s product candidates or adversely affect AGTC’s ability to conduct its business. Additional factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading “Item 1A—Risk Factors” in AGTC’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management’s plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, AGTC assumes no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

IR/PR CONTACTS:

David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
dcarey@lazarpartners.com or dlewis@lazarpartners.com

Corporate Contacts:

Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
lbullock@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

(ADAP) Appoints Leading Immunotherapy Experts from United States and Europe

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016  — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology experts from across the United States and Europe to its newly formed scientific advisory board (SAB). Crystal Mackall, M.D., Professor of Pediatrics and Medicine and Associate Director of the Stanford Cancer Institute, will serve as Chair of the SAB.

The SAB will serve as a strategic resource for Adaptimmune and help to steer the company’s development efforts in the field of immuno-oncology.

“Adaptimmune is the clear leader in the TCR T-cell therapy space, and I’m very pleased to join their scientific advisory board as Chair at this important time in their evolution,” said Dr. Mackall.

“Our inaugural scientific advisory board members bring a wealth of experience in areas including gene therapy, immunotherapy and oncology, and we are honored to have such a prestigious group of advisors,” said James Noble, Adaptimmune’s Chief Executive Officer. “Their insights and guidance will be invaluable as we continue to move our pipeline of affinity optimized T-cell therapies forward.”

The inaugural members of Adaptimmune’s scientific advisory board are:

• Crystal Mackall, M.D., Chair, Adaptimmune Scientific Advisory Board; Professor of Pediatrics and Medicine; Associate Director of the Stanford Cancer Institute
• Nabil Ahmed, M.D., Associate Professor, Department of Pediatrics, Texas Children’s Hospital, Texas Children’s Cancer Center; Center for Cell and Gene Therapy, Houston Methodist Hospital, Baylor College of Medicine
• Michael Dustin, Ph.D., Professor of Immunology and Wellcome Principal Research Fellow, Director of Research of the Kennedy Institute
• Keith Flaherty, M.D., Professor, Medicine, Harvard Medical School; Director of Termeer Center for Target Therapy, Cancer Center, Massachusetts General Hospital
• Wolf Fridman, M.D., Ph.D., Professor Emeritus of Immunology, Paris Descartes University Medical School, Paris, France; President, Canceropole Ile de France
• Thomas Gajewski, M.D., Ph.D., Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine – Section of Hematology/Oncology, University of Chicago Medical Center
• Stephan Grupp, M.D., Ph.D., Novotny Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine; Director, Cancer Immunotherapy Frontier Program; Director of Translational Research, Children’s Hospital of Philadelphia
• Arlene Sharpe, M.D., Ph.D., Fabyan Professor of Comparative Pathology, Microbiology and Immunobiology, Harvard Medical School; Vice Chair for Education, Pathology, Harvard Medical School; Co-Director, Harvard Institute of Translation Immunology (HITI), Harvard Medical School
• Mario Sznol, M.D., Professor, Internal Medicine; Leader, Disease-Related Research Team, Melanoma and Renal cell Carcinoma; Vice-Chief, Medical Oncology; Co-Director, Yale Skin SPORE, Yale Cancer Center

About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase I/II trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on October 13, 2015 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T:  (215) 825-9306  
E: will.roberts@adaptimmune.com

Margaret Henry 
Head of PR 
T: +44 (0)1235 430036 
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

(RESN) Signing of Securities Purchase Agreement to Raise up to $6 Million

Resonant Inc. (NASDAQ: RESN), a developer of innovative filter designs for radio frequency front-ends (RFFEs) for the mobile device industry, today announced it has entered into a definitive agreement with various institutional and individual accredited investors and certain of its officers and directors to raise gross proceeds of up to $6 million in a private placement of units at a per-unit price of $2.985 (the Offering).

Each unit consists of one share of the Company’s common stock, par value $0.001 per share (Common Stock), and one warrant to purchase one share of Common Stock at an exercise price of $2.86 per share. The warrant is exercisable for a period commencing six months and ending three years from the date of the closing of the Offering. Resonant anticipates using the net proceeds from the fund raising to continue its product development efforts and business development activities, and for general and administrative purposes.

National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), and Drexel Hamilton, LLC are acting as co-placement agents for the Offering.

The Offering is expected to close on or prior to April 26, 2016, subject to satisfaction of customary closing conditions. The warrants will not be separately listed for trading. Details of the Offering will be included in a Current Report on Form 8-K filed shortly after closing.

Resonant will be required to file a resale registration statement with the Securities and Exchange Commission within 30 days following the closing that covers the resale by the purchasers of the shares of Common Stock, and the shares of Common Stock underlying the warrants, purchased by them in the Offering.

The securities offered in the Offering have not been registered under the Securities Act of 1933 or applicable securities laws of any state or jurisdiction. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable securities laws of any state or jurisdiction. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Resonant^® Inc.

Resonant is creating innovative filter designs for the RFFE for the mobile device industry. The RFFE is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital baseband. Filters are a critical component of the RFFE that selects the desired radio frequency signals and rejects unwanted signals and noise. For more information, please visit www.resonant.com.

About Resonant’s ISN® Technology

Resonant can create designs for hard bands and complex requirements that can be manufactured for half the cost and developed in half the time of traditional approaches. The Company’s large suite of proprietary mathematical methods, software design tools and network synthesis techniques enable the ability to explore a much bigger set of possible solutions and quickly derive the better ones. These improved filters still use existing manufacturing methods (i.e. SAW) and can perform as well as those using higher cost methods (i.e. BAW). While most of the industry designs surface acoustic wave filters using a coupling-of-modes model, Resonant uses circuit models and physical models. Circuit models are computationally much faster, and physical models are highly accurate models based entirely on fundamental material properties and dimensions. Resonant’s method delivers excellent predictability, enabling achievement of the desired product performance in roughly half as many turns through the fab. In addition, because Resonant’s models are fundamental and therefore speak the “fab language” of basic material properties and dimensions, integration with foundry partners and fab customers is eased.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements regarding the expected closing of the private placement and the intended use of proceeds from the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the satisfaction of the conditions to closing of the offering, risks associated with the cash requirements of our business and other risks detailed from time to time in our filings with the Securities and Exchange Commission, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

(GSAT) to Participate in 20th Annual Burkenroad Reports Investment Conference

COVINGTON, La., April 22, 2016 — Globalstar Inc. (NYSE MKT:GSAT) announced today that it will participate in the 20^th Annual Burkenroad Reports Investment Conference in New Orleans, LA. Jay Monroe, Chairman and CEO, will present at 11:00 a.m. CDT at the New Orleans Ritz-Carlton Hotel on Friday, April 22, 2016.

A copy of the presentation will be made available on the Investor Relations page of Globalstar’s website.

About Globalstar, Inc.
Globalstar is a leading provider of mobile satellite voice and data services, leveraging the world’s newest mobile satellite communications network. Customers around the world in industries like government, emergency management, marine, logging, oil & gas and outdoor recreation rely on Globalstar to conduct business smarter and faster, maintain peace of mind and access emergency personnel.  Globalstar data solutions are ideal for various asset and personal tracking, data monitoring and SCADA applications.  The Company’s products include mobile and fixed satellite telephones, the innovative Sat-Fi satellite hotspot, Simplex and Duplex satellite data modems, tracking devices and flexible service packages.  For more information, visit www.globalstar.com.

Note that all SPOT products described in this press release are the products of SPOT LLC, which is not affiliated in any manner with Spot Image of Toulouse, France or Spot Image Corporation of Chantilly, Virginia. For more information, visit www.globalstar.com.

Investor Contact Information:
Email: investorrelations@globalstar.com 
Phone: (985) 335-1538

(ARTX) ISS Recommends Shareholders Vote “FOR” Management Proposals

ANN ARBOR, Mich., April 21, 2016  — Arotech Corporation (Nasdaq GM: ARTX) today announced that Institutional Shareholder Services (“ISS”) has joined another leading independent proxy advisory firm in recommending that shareholders vote “FOR” on all three proposals being presented by Arotech’s Board of Directors at the Annual Meeting of Shareholders to be held on May 4, 2016. Specifically, ISS has recommended a vote for the election of the proposed Class III director nominees, ratification of the appointment of the Company’s independent auditors and the compensation of the Company’s executive officers.

“After a thorough and independent review, ISS has recommended voting in favor of all of the matters to be presented at our annual shareholders meeting,” said Steven Esses, President and CEO of Arotech. “Each of the three proposals supports our commitment to transparency, independence and strong corporate governance. This is the second independent institutional investor research organization to have recommended in favor of all of the board’s proposals.”

The Company filed its definitive proxy statement relating to the Annual Meeting (the “Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) on March 30, 2016.  Shareholders can obtain the Proxy Statement, any amendments or supplements to the Proxy Statement and other documents filed by the Company with the SEC for no charge at the SEC’s website at www.sec.gov and at the Company’s website at www.arotech.com.

Shareholders are urged to vote “FOR” the three proposals. Shareholders may vote by telephone, Internet or by returning a signed proxy or voting instruction form by mail. Investors with questions regarding how to vote their shares may contact the firm’s proxy solicitor, Alliance Advisors LLC, at 973.873.7700.

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation, and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan, and research, development and production subsidiaries in Michigan, South Carolina, and Israel. For more information on Arotech, please visit Arotech’s website at www.arotech.com.

Arotech Investor Relations Contacts:

Brett Maas / Rob Fink
Hayden IR
(646) 536.7331 / (646) 415.8972
ARTX@haydenir.com

Except for the historical information herein, the matters discussed in this news release include forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, readers are cautioned not to place undue reliance on these forward-looking statements, as they are subject to various risks and uncertainties that may cause actual results to vary materially. These risks and uncertainties include, but are not limited to, risks relating to: product and technology development; the uncertainty of the market for Arotech’s products; changing economic conditions; delay, cancellation or non-renewal, in whole or in part, of contracts or of purchase orders (including as a result of budgetary cuts resulting from automatic sequestration under the Budget Control Act of 2011); and other risk factors detailed in Arotech’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and other filings with the Securities and Exchange Commission. Arotech assumes no obligation to update the information in this release. Reference to the Company’s website above does not constitute incorporation of any of the information thereon into this press release.

(VIAB) & (HAS) Tap Top Group Of Writers To Create Cross-Property Film Universe

HOLLYWOOD, Calif., April 21, 2015  — Paramount Pictures and Hasbro, Inc. today unveiled its top talent writers room which will have responsibility for developing Hasbro’s cross-property interconnected onscreen universe featuring the brands G.I. Joe, Micronauts, Visionaries, M.A.S.K. (Mobile Armored Strike Kommand) and ROM. This group includes some of the most notable creative talent in Hollywood, including Academy Award Winner Akiva Goldsman (A Beautiful Mind), who will have responsibility for overseeing the writers room on behalf of Hasbro and Paramount as well as serving as Executive Producer for all of the films. Joining Goldsman will be Lindsey Beer (Wizard of Oz, Kingkiller Chronicle), Pulitzer Prize Winner Michael Chabon (The Amazing Adventures of Kavalier & Clay), Cheo Coker (Luke Cage, Ray Donovan), Joe Robert Cole (Black Panther, People vs. OJ), Nicole Perlman (Guardians of the Galaxy, Captain Marvel), Jeff Pinkner (Lost, The Dark Tower), Nicole Riegel (LYNCH), Geneva Robertson (Atlantis, Tomb Raider) and Brian K Vaughan (Under the Dome, Lost).

Allspark Pictures, Hasbro’s film label, plans to produce films based on this cross-property universe, with Brian Goldner (Chairman, President and CEO, Hasbro) and Stephen Davis (Executive Vice President and Chief Content Officer, Hasbro) serving as Producers, and Josh Feldman (Co-Head of Storytelling, Hasbro) as Co-Executive Producer. Hasbro will also deploy in the room an unprecedented team of its top artists and designers to assist Goldsman and the writers to visualize this all-new cinematic universe.

“Paramount and Hasbro have partnered on many successful films in the past, including the ‘TRANSFORMERS’ and ‘G.I. JOE,’ franchises,” said Brad Grey, Chairman and CEO of Paramount Pictures. “Bringing together a writers room of this caliber is a bold step for our partnership, and one that we believe is critical for building these brands into new, successful franchises for the future.”

“Together with Paramount, we have assembled a team of incredibly talented creative minds and storytellers to continue to help tell the rich history and narrative behind this interconnected cinematic universe, and we are thrilled to be working with Akiva Goldsman again to guide this process,” said Brian Goldner. “We are also excited to partner with Paramount to produce the films, as we’ve had a strong and collaborative partnership since our first Transformers movie in 2007.”

The Paramount and Hasbro partnership is responsible for the worldwide blockbuster success of the “TRANSFORMERS” franchise, which has earned $3.8 billion to-date, and whose films, directed by Michael Bay, are amongst the highest grossing movies of all time; and the “G.I. JOE” franchise, which have earned more than $675 million worldwide.

About Paramount Pictures Corporation

Paramount Pictures Corporation (PPC), a global producer and distributor of filmed entertainment, is a unit of Viacom (NASDAQ: VIAB, VIA), a leading content company with prominent and respected film, television and digital entertainment brands. Paramount controls a collection of some of the most powerful brands in filmed entertainment, including Paramount Pictures, Paramount Animation, Paramount Television, Paramount Vantage, Paramount Classics, Insurge Pictures, MTV Films, and Nickelodeon Movies. PPC operations also include Paramount Home Media Distribution, Paramount Pictures International, Paramount Licensing Inc., and Paramount Studio Group.

ABOUT HASBRO

Hasbro (NASDAQ: HAS) is a global company committed to Creating the World’s Best Play Experiences, by leveraging its beloved brands, including LITTLEST PET SHOP, MAGIC: THE GATHERING, MONOPOLY, MY LITTLE PONY, NERF, PLAY-DOH and TRANSFORMERS, and premier partner brands. From toys and games, television programming, motion pictures, digital gaming and lifestyle licensing, Hasbro fulfills the fundamental need for play and connection with children and families around the world. The Company’s Hasbro Studios and its film label, ALLSPARK PICTURES, create entertainment brand-driven storytelling across mediums, including television, film, digital and more. Through the company’s commitment to corporate social responsibility, including philanthropy, Hasbro is helping to build a safe and sustainable world and to positively impact the lives of millions of children and families. Learn more at www.hasbro.com, and follow us on Twitter (@Hasbro & @HasbroNews) and Instagram (@Hasbro).

Media Contact:
Katie Martin Kelley
(323) 956-2821
kmk@paramount.com

Julie Duffy
(401) 727-5931
Julie.Duffy@hasbro.com

Melissa Schumer/Mat Newman
(310) 854-8154/(310) 854-8198
mschumer@rogersandcowan.com
mnewman@rogersandcowan.com

(AMD) PC Gaming Showcase to Return to LA During E3 in Second Annual PC Gaming Show

(CXRX) Announces Formation of Special Committee to Review Strategic Alternatives

OAKVILLE, ON, April 21, 2016  – Concordia Healthcare Corp. (“Concordia” or the “Company”) (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced it has formed a special committee of independent members of the Board of Directors of the Company (the “Special Committee”) to consider various strategic alternatives potentially available to the Company.

The Company has had discussions, however, there can be no assurance that any transaction will occur.  Concordia does not intend to make any additional comments at this time regarding various strategic alternatives potentially available to the Company.

About Concordia

Concordia is a diverse, international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established off-patent molecules. Concordia also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin® for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications.

Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.

Notice regarding forward-looking statements and information:

This news release includes forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws, regarding Concordia and its business, which may include, but are not limited to any strategic alternatives potentially available to the Company. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks relating to Concordia’s securities, Concordia’s growth, risks associated with the use of Concordia’s products, increased leverage, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically or through M&A, the inability to repay debt and/or satisfy future obligations (including, without limitation, earn out obligations), risks associated with Concordia’s outstanding debt, risks associated with the geographic markets in which Concordia operates, the pharmaceutical industry and the regulation thereof, economic factors, the equity and debt markets generally, general economic and stock market conditions, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks and uncertainties detailed from time to time in Concordia’s filings with the Securities and Exchange Commission and the Canadian Securities Administrators, and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events, or otherwise.

(CNCK) Dr. Goran Skog Joins Content Checked’s Board of Directors

(REI) Announces Common Stock Offering

Ring Energy, Inc. (NYSE MKT: REI) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering. The underwriters will have a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from the offering to fund a pilot horizontal drilling program, repay debt under its revolving credit facility and for general corporate purposes.

SunTrust Robinson Humphrey, Inc. and Seaport Global Securities LLC are acting as joint book-running managers in the offering.

The offering will be made only by means of a prospectus supplement and accompanying base prospectus to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A copy of the preliminary prospectus supplement and accompanying base prospectus for the offering will be filed with the SEC and may be obtained from the SEC’s website at http://www.sec.gov. In addition, copies may be obtained, when available, by contacting (i) SunTrust Robinson Humphrey, 3333 Peachtree Road NE, 9^th Floor, Atlanta, GA 30326, Attention: Prospectus Department; email: strh.prospectus@suntrust.com; telephone: 404-926-5744; or fax: 404-926-5464 or (ii) Seaport Global Securities LLC, 360 Madison Avenue, 21^st Floor, New York, NY 10017; or telephone: 646-264-5601.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Ring Energy, Inc.

Ring Energy, Inc. is an oil and gas exploration, development and production company with current operations in Texas and Kansas.

www.ringenergy.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve a wide variety of risks and uncertainties, including, without limitations, statements with respect to the Company’s strategy and prospects. Such statements are subject to certain risks and uncertainties which are disclosed in the Company’s reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2015, and its other filings with the SEC. Readers and investors are cautioned that the Company’s actual results may differ materially from those described in the forward-looking statements due to a number of factors, including, but not limited to, the Company’s ability to acquire productive oil and/or gas properties or to successfully drill and complete oil and/or gas wells on such properties, general economic conditions both domestically and abroad, the conduct of business by the Company, and other factors that may be more fully described in additional documents set forth by the Company.

(SHLD) Kenmore®, Craftsman® And DieHard® Debut Connected Home Products

Trusted Brands Deliver Solutions to Make Members’ Lives Easier and Provide Peace-Of-Mind, While Saving Time and Money

HOFFMAN ESTATES, Ill., April 20, 2016  — For generations, the Kenmore, Craftsman and DieHard brands have provided homeowners with the appliances, tools and power needed to make their house a home. Today, the brands announced they will introduce five affordable connected products designed to protect the home and garage, provide peace-of-mind, and save time, energy and money.

“The Kenmore, Craftsman and DieHard brands are part of the fabric of American homes,” said Tom Park, president of Kenmore, Craftsman and DieHard brands at Sears Holdings. “Our members rely on our products’ quality and performance not only in their daily lives, but for years to come. We’re excited to unveil these new, connected products designed to meet the needs of the modern homeowner, making home management easier and more cost-effective.”

The initial product offering includes:
Kenmore, an industry leader in delivering trusted performance:

• Kenmore Elite^® Smart Room Air Conditioner
• Kenmore Smart Water Heater Module
• Kenmore Elite Smart Hybrid Water Softener

Craftsman, America’s most trusted tool brand:

• Wireless-enabled Craftsman Zero Turn Steerable Riding Mower

DieHard, America’s most trusted, reliable and preferred vehicle battery brand:

• DieHard Smart Charger and Maintainer

Easy-to-use apps will also be introduced to provide homeowners with remote access from their smartphone or tablet to monitor efficiencies and adjust product settings, which can lead to energy cost savings.

The Kenmore Elite Smart Room Air Conditioner is available now, with the additional products to follow. The connected products will be available in select Sears stores nationwide and online at Sears.com as part of its Connected Solutions offering, which provides ways for members to streamline their routine, save money and put control of their home in the palm of their hand.

Kenmore Elite 8,000 BTU Smart Room Air Conditioner

• The Kenmore Elite Smart Room Air Conditioner offers a stylish new design that allows members to cool their homes from almost anywhere using the Kenmore AC™ app. With wireless accessibility from a smartphone or tablet, members can:
  • Control on the go: Remotely turn product on and off, set a schedule or adjust temperature while away.
  • Conserve energy: Smart technology provides the ability to run only when needed, saving energy and money.
  • Model: 77082
  • MSRP: $299.99

Kenmore Smart Water Heater Module

• The Kenmore Smart Water Heater Module allows members to connect to select new and existing Kenmore and Kenmore Elite Water Heaters to monitor and adjust home water temperature and usage. The Kenmore Smart Control app will assist users with:
  • Energy savings: Save energy and money on hot water generation by adjusting the temperature setting on the water heater when away from home.
  • Water monitoring: View available hot water levels to monitor how much hot water is left.
  • Model: 58000
  • MSRP: $69.99                                                                   

Kenmore Elite Smart Hybrid Water Softener

• The Kenmore Elite Smart Hybrid Water Softener allows homeowners to monitor salt levels and water usage remotely to prevent wasted resources. This water softener connects to the Kenmore Smart Control app to help users:
  • Manage salt levels: Monitor the inner salt supply and eliminate the surprise of an unexpected need for replenishment.
  • Water flow rate monitoring: Keep informed on water flow rate, current day water usage and average daily water usage to easily identify excessive usage and unexpected continuous water flow.
  • Model: 38620
  • MSRP: $799.99

Wireless-enabled Craftsman Zero Turn Steerable Riding Mowers

• The Craftsman Zero Turn Steerable Riding Mowers are designed for ease of use, especially when mowing large yards with obstacles. These wireless-enabled riding mowers connect with a smartphone or tablet via the new Craftsman Connect app to help riders in the following ways:
  • Maintenance checks: Notification alerts members when it’s time to change the oil, replace the air filter, check blades and wheel alignment, schedule maintenance, and more.
  • Product care: View do-it-yourself maintenance videos and step-by-step tutorials on changing blades, replacing the air filter and changing oil.
  • Product information: Owner’s manual, parts, attachments and accessories list.
  • Model:
    • 22 HP V-Twin 42-in. Zero Turn Steerable Riding Mower: 20400
    • 23 HP V-Twin 50-in. Zero Turn Steerable Riding Mower: 20410
  • MSRP
    • 22 HP V-Twin 42-in. Zero Turn Steerable Riding Mower: $2,799
    • 23 HP V-Twin 50-in. Zero Turn Steerable Riding Mower: $3,199

DieHard Smart Charger and Maintainer

• The DieHard Smart Charger and Maintainer allows members to monitor their motorcycle, car or boat’s battery health remotely, all with their smart phone or tablet. Equipped with auto voltage detection, members can now use one DieHard Smart Charger and Maintainer for 6-volt and 12-volt batteries.
  • Stay charged: Automatically keeps batteries fully charged and maintained at all times.
  • Digital Scrolling Display: An alphanumeric display guides members through the charging process eliminating the guesswork.
  • Model: DH111
  • MSRP: $99.99

Additional Kenmore, Craftsman and DieHard connected products will arrive in stores throughout the remainder of 2016.

For more information about current and future smart products visit Kenmore.com/Smart. The complete line of Kenmore appliances can also be found online at Kenmore.com; Craftsman tools at Craftsman.com; and DieHard products at DieHard.com.

About the Kenmore Brand

The Kenmore Brand is an industry leader in delivering trusted performance in the home with smart and stylish appliance innovations that help consumers do things quicker, easier and better. Recognized as a top appliance brand for over 100 years, the Kenmore brand continues to give consumers more time, efficiency and improved results for better living with industry-leading products across small and large appliance categories. For more information, visit www.kenmore.com, www.cookmore.com/press-kit/ or www.facebook.com/kenmore.

About the Craftsman Brand

The Craftsman brand is America’s most trusted tool brand. For more than 88 years, the Craftsman brand has developed innovative tools and products, earning a reputation for unsurpassed quality and durability, trusted for generations. The Craftsman brand offers a full range of hand and power tools that meet the needs of the DIY user to the demanding professional. In addition, the Craftsman brand also offers lawn and garden products and tool storage. The Craftsman brand also has a free membership program called Craftsman Club^® which gives tool enthusiasts access to exclusive deals, members-only projects, expert tips and news on the latest tool innovations from the brand. Craftsman Club is part of the Shop Your Way^® network, so points can be redeemed for purchases at Sears and Kmart and online at Craftsman.com. For more information, visit www.CraftsmanClub.com.

About the DieHard brand

DieHard is America’s most trusted, reliable and preferred vehicle battery brand. Introduced in 1967, Sears designed the DieHard automotive battery to produce 35 percent more usable starting power than other similar batteries. Featuring a revolutionary tough, thin-walled case of translucent polypropylene plastic, which was 50 percent thinner than conventional black rubber-type battery enclosures, the design’s extra room meant bigger plates, more acid and extra starting power. During testing, not a single failure was reported in over 26,000 starts in temperatures ranging from sub-zero to more than 100 degrees, hence the name “DieHard.” See more about DieHard at www.DieHard.com.

About Sears Holdings Corporation

Sears Holdings Corporation (NASDAQ: SHLD) is a leading integrated retailer focused on seamlessly connecting the digital and physical shopping experiences to serve our members – wherever, whenever and however they want to shop. Sears Holdings is home to Shop Your Way^®, a social shopping platform offering members rewards for shopping at Sears and Kmart as well as with other retail partners across categories important to them. The Company operates through its subsidiaries, including Sears, Roebuck and Co. and Kmart Corporation, with full-line and specialty retail stores across the United States. For more information, visit www.searsholdings.com.

Larry Costello
PR Director
847-286-9036
Larry.Costello@searshc.com

Andrew Scutt
Zeno Group for Kenmore
312-245-0688
Andrew.Scutt@zenogroup.com

(ARTX) Wins Marine Corps Contract, $40 Million IDIQ Award

UEC Electronics Mobile Electric Hybrid Power Sources (MEHPS) Systems to provide Marine Corp with more efficient portable solution

ANN ARBOR, Mich., April 20, 2016  — Arotech Corporation (Nasdaq GM: ARTX) today announced that its U.S. Power Systems Division, UEC Electronics, has recently received a $2.6 million contract from the Marine Corps to design, develop and deliver four MEHPS systems.

MEHPS portable solutions combine battery technology with existing generator and solar solutions to power forward deployed units. The MEHPS product harnesses solar power and intelligently reduces run-time on generators, reducing fuel consumption and extending generator life.

“The Department of Defense continues to advance initiatives that will increase energy efficiency and enable our forces to perform missions, while acknowledging energy as a potential vulnerability,” said Steven Esses, President and CEO of Arotech. “Demand for renewable and hybrid energy power generation systems continues to grow and Arotech is well positioned to capitalize on a significant opportunity. This contract award is a testament to our team and the performance of our product. We are excited about this opportunity and are optimistic that this award could lead to additional orders in the future.”

UEC Electronics previously designed and developed a smaller hybrid power solution for the Marine Corps. The 1kW Ground Renewable Expeditionary Energy Network System (GREENS) is now being produced by UEC under a $40.8 million IDIQ contract.

This latest MEHPS award is for a scalable (up to 15kW) design for use at forward operating bases and is a significant part of the DoD’s strategy to reduce fuel consumption by 25% prior to 2025. The Marine Corp’s roadmap calls for MEHPS production beginning in 2018.

International customers are watching the MEHPS program as well.  MEHPS was one of four “pathfinder” projects announced by Prime Minister Modi (India) and President Obama in January 2015 under the Defense Technology and Trade Initiative.

About Arotech’s Power Systems Division
Arotech’s Power Systems Division is a leading provider of primary and rechargeable batteries and chargers for defense and other military applications and of electronic components and subsystems primarily for military, aerospace and industrial customers. Arotech develops and produces high power zinc-air batteries and is believed to be the sole supplier of this technology to the U.S. military. In addition, Arotech develops high-end primary and secondary batteries and associated chargers, as well as (i) hybrid power generation systems, (ii) smart power subsystems for military vehicles and dismounted applications, and (iii) aircraft and missile systems support for cutting-edge weapons and communications technologies, and has vast experience in working with government agencies, the military and large corporations. The Power Systems Division consists of Electric Fuel Battery Corporation (www.efbpower.com), Epsilor-Electric Fuel Ltd. (www.epsilor.com; www.electric-fuel.com), and UEC Electronics, LLC (www.uec-electronics.com).

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation, and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan, and research, development and production subsidiaries in Michigan, South Carolina, and Israel. For more information on Arotech, please visit Arotech’s website at www.arotech.com.

U.S. Power Systems Division Contact:

Nancy Straight
Business Development Manager
843-552-8682
nancystraight@uec-electronics.com

Arotech Investor Relations Contacts:

Brett Maas / Rob Fink
Hayden IR
(646) 536.7331 / (646) 415.8972
ARTX@haydenir.com

Arotech Training and Simulation Division Announces IDIQ Award Valued at up to $40 Million

ANN ARBOR, Mich., April 20, 2016  — Arotech Corporation [Nasdaq GM: ARTX] announced that its Training and Simulation Division (ATSD) has received an Indefinite Delivery Indefinite Quantity (IDIQ) award with a potential value of up to $40M for its MILO Range Training Systems’ simulator products. The multiple-award contract is for the provision of law enforcement training simulators and related equipment and services to the U.S. Department of State in support of its Bureau of International Narcotics and Law Enforcement Affairs (INL) training mission. INL works to keep Americans safe at home by countering international crime, illegal drugs, and instability abroad. INL provides training and assistance in all aspects of police, corrections and justice systems tailored to the specific environment, legal framework, and identified requirements of each partner nation.  MILO Range Training Systems was one of two awardees following a competitive full and open solicitation.  The Period of performance is five years and includes MILO Range Theater multi-screen and MILO Range portable solutions.

“We are thrilled with this award, which solidifies our long standing position as a supplier to the Department of State for our award winning MILO Range Training Systems,” commented Robert McCue, MILO Range Training Systems General Manager. “This highly competitive procurement further validates our position as a global leader in the international law enforcement judgmental skills simulator market, and provides a streamlined acquisition process to deliver this important training capability to the various organizations supported by the U.S. Department of State.”

About Arotech’s Training and Simulation Division

Arotech’s Training and Simulation Division (ATSD) provides world-class simulation based solutions. ATSD develops, manufactures, and markets advanced high-tech multimedia and interactive digital solutions for engineering, use-of-force, and operator training simulations for military, law enforcement, security, municipal and private industry personnel. The division’s fully interactive operator training systems feature state-of-the-art vehicle simulator technology enabling training in situation awareness, risk analysis and decision-making, emergency reaction and avoidance procedures, conscientious equipment operation, and crew coordination. The division’s use-of-force training products and services allow organizations to train their personnel in safe, productive, and realistic environments. The division supplies pilot decision-making support software for the F-15, F-16, F-18, F-22, and F-35 aircraft, simulation models for the ACMI/TACTS air combat training ranges, and Air-Refueling Boom Arm simulators. The division also provides consulting and developmental support for engineering and research simulation solutions.

Arotech’s Training and Simulation Division consists of FAAC Incorporated (www.faac.com), MILO Range Training Systems (www.milorange.com), and Realtime Technologies (www.simcreator.com).

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation, and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan, and research, development and production subsidiaries in Michigan, South Carolina, and Israel. For more information on Arotech, please visit Arotech’s website at www.arotech.com.

Investor Relations Contacts:

Brett Maas / Rob Fink
Hayden IR
(646) 536.7331 / (646) 415.8972
ARTX@haydenir.com

Except for the historical information herein, the matters discussed in this news release include forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, readers are cautioned not to place undue reliance on these forward-looking statements, as they are subject to various risks and uncertainties that may cause actual results to vary materially. These risks and uncertainties include, but are not limited to, risks relating to: product and technology development; the uncertainty of the market for Arotech’s products; changing economic conditions; delay, cancellation or non-renewal, in whole or in part, of contracts or of purchase orders (including as a result of budgetary cuts resulting from automatic sequestration under the Budget Control Act of 2011); and other risk factors detailed in Arotech’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and other filings with the Securities and Exchange Commission. Arotech assumes no obligation to update the information in this release. Reference to the Company’s website above does not constitute incorporation of any of the information thereon into this press release.

(OCLS) Receives U.S. FDA Approval for Lasercyn™

PETALUMA, Calif., April 20, 2016 — Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new Microcyn®-based Lasercyn™ Gel.  Under the supervision of a healthcare professional, Lasercyn Gel is intended for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.

Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Research Center, all located in Nashville, Tennessee, commented, “Lasercyn is a promising new tool for all aesthetic dermatologists who are looking to better manage post-laser itch and pain associated with laser skin resurfacing, along with enhanced healing. In our clinical testing of Lasercyn to date, we have seen dramatically improved outcomes with quicker healing times and less patient discomfort when Lasercyn is added to the post-procedure management protocol.”

Oculus will begin marketing Lasercyn via its own U.S. dermatology sales team beginning in the summer of 2016.

About Laser Skin Resurfacing
According to the Clinical, Cosmetic and Investigational Dermatology Journal, medical and aesthetic skin procedures have seen a steady surge within the last decade, and a higher demand for skin rejuvenation practices. In 2013 in the United States, dermatologic surgeons performed over 9.5 million treatments, an almost 22% increase from the previous year, with a rising number of treatments involving skin resurfacing in the areas of laser/light/energy-based procedures (2.25 million), chemical peels (1.1 million), and microdermabrasion (974,000).

Laser skin resurfacing, also known as a laser peel, laser vaporization and lasabrasion, can reduce facial wrinkles, scars and blemishes. Newer laser technologies provide surgeons with a new level of control in laser surfacing, permitting extreme precision, especially in delicate areas.  The laser beam used in laser resurfacing will remove outer layer of skin, called the epidermis. It simultaneously heats the underlying skin, called the dermis. This action works to stimulate growth of new collagen fibers. As the treated area heals, the new skin that forms is smoother and firmer.

Common side effects include redness of the skin, swelling of the treated area, itch, pain and moderate irritation similar to the feeling produced by a mild sunburn.

About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.

Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “marketing” and “looking,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s common stock and warrants may be delisted from NASDAQ, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 30, 2015. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Oculus®, Microcyn® Technology and Lasercyn™ are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Oculus Innovative Sciences, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com

(UNXL) Wins Fourth 2016 Program From Tier 1 US PC Manufacturer

XTouch™ and Diamond Guard™ chosen to enhance stylus performance

SANTA CLARA, Calif., April 20, 2016  UniPixel, Inc. (NASDAQ: UNXL), a provider of advanced touch solutions to the touchscreen and flexible electronics markets, today announced a new design win from a leading U.S. PC manufacturer for a 13.3-inch laptop computer. The new laptop will feature UniPixel’s XTouch touch screen sensors with Diamond Guard hardcoat in an advanced laptop design. This program represents the fourth win in 2016 with this customer and further expands our business footprint with this leading manufacturer.

Jeff Hawthorne, president and chief executive officer of UniPixel, said, “We now have two major customers that have awarded us four programs each thus far in 2016. We are gratified that these existing customers, both industry leaders, value our technology enough to award us multiple programs. The increasing acceptance of our products not only demonstrates the performance attributes of our highly differentiated products, but it also validates our manufacturing capabilities to support the needs of our customers to create the leading-edge devices that their end-user consumers demand.”

UniPixel’s highly responsive XTouch touchscreen sensor technology with its outstanding finger-touch and capacitive stylus performance, in conjunction with the company’s Diamond Guard hardcoat technology which reduces overall cost and weight, will enable this manufacturer to produce a superior new 13.3-inch laptop computer. Volume production for this program is expected to commence during the fourth calendar quarter of 2016.

About UniPixel
UniPixel, Inc. (NASDAQ: UNXL) develops and markets Performance Engineered Films for the touch screen and flexible electronics markets. The company’s roll-to-roll electronics manufacturing process patterns fine line conductive elements on thin films. The company markets its technologies for touch panel sensor, cover glass replacement, and protective cover film applications under the XTouch™ and Diamond Guard™ brands. For further information, visit www.unipixel.com.

Forward-looking Statements
All statements in this news release that are not based on historical fact are “forward-looking statements” within the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including the statement that UniPixel’s integrated technologies are expected to provide enhanced yields at a lower cost, thereby expanding UniPixel’s competitiveness in the touch screen market.  While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015. UniPixel operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the company’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and Current Reports on Form 8-K.

Trademarks in this release are the property of their respective owners

Contact:
Joe Diaz, Robert Blum, Joe Dorame
Lytham Partners, LLC
602-889-9700
unxl@lythampartners.com

(SGYP) Acceptance of NDA for Plecanatide for Plecanatide

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the U.S. Food and Drug Administration (FDA) has determined that the company’s New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.

“This is a transformative milestone for our company and reflects our relentless commitment to bringing meaningful treatment options to patients suffering from GI diseases,” said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals. “If approved, we believe plecanatide will become an important new treatment option that will benefit patients with CIC. I want to thank the Synergy employees and outside consultants working on the CIC NDA for their hard work and dedication which contributed to this important milestone.”

The NDA for plecanatide is supported by two double-blind placebo-controlled phase 3 trials and one open-label long term safety study. A total of more than 2,700 patients with CIC received a once-daily dose of either plecanatide or placebo across the two placebo-controlled trials. Additionally, over 3,500 patients were exposed to plecanatide in the CIC clinical development program.

About Plecanatide

Plecanatide is our first uroguanylin analog currently being evaluated for use as a once-daily tablet for the treatment of two functional GI disorders, CIC and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally similar to uroguanylin with the exception of a single amino acid change. Plecanatide is designed to replicate the function of uroguanylin, a naturally occurring GI peptide, by working locally in the upper GI tract to stimulate digestive fluid movement and support regular bowel function. In 2015, we announced positive phase 3 data with plecanatide in two pivotal CIC clinical trials and on January 29, 2016 the company filed its first NDA for plecanatide in CIC. We presently have two ongoing phase 3 clinical trials with plecanatide in IBS-C and intend to file our second NDA in IBS-C by the end of this year. We expect top-line data results from both pivotal IBS-C trials in the third quarter of this year.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. Our proprietary GI platform is based on uroguanylin and includes two lead product candidates – plecanatide and dolcanatide. Dolcanatide is our second uroguanylin analog currently being explored for inflammatory bowel disease. Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine. In January 2016, we announced positive data with dolcanatide in a phase 1b trial with ulcerative colitis patients. For more information, please visit www.synergypharma.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward- looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on Synergy’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy’s Form 10-K for the year ended December 31, 2015 and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Synergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Synergy Pharmaceuticals:
Gem Hopkins, 212-584-7610
VP, Investor Relations and Corporate Communications
ghopkins@synergypharma.com

(TGEN) Schedules Earnings Release and Conference Call for Q1 2016 Results

WALTHAM, Mass., April 19, 2016  — Tecogen^® Inc. (NASDAQ: TGEN) will release its financial results for the first quarter of 2016 on Wednesday, May 11, 2016. The earnings press release and supplemental earnings call slides will be available on the Company website at www.Tecogen.com in the “Investor Relations” section under “About Us.” Members of Tecogen’s senior management will hold a conference call and webcast on the same day at 11:00 AM Eastern Time to discuss the company’s first quarter financial performance.

The conference call will be available live via telephone and webcast. To listen to the audio portion, dial (888) 349-0103 within the U.S., (855) 669-9657 from Canada, or + (412) 902-0129 from other international locations. Participants should ask to be joined to the Tecogen Inc. earnings call. Please begin dialing at least 10 minutes before the scheduled starting time. Alternately, to register for and listen to the webcast, go to http://investors.tecogen.com/webcast.

The earnings conference call will be recorded and available for playback one hour after the end of the call through Wednesday, May 18^th, 2016.  To listen to the playback, dial (877) 344 7529 within the U.S., (855) 669-9658 from Canada, or (412) 317-0088 outside the U.S. and use Replay Access Code 10084852. Following the call, the webcast will be archived for 30 days.

About Tecogen
Tecogen manufactures, installs, and maintains high efficiency, ultra-clean, combined heat and power products including natural gas engine-driven cogeneration, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer’s carbon footprint.

In business for over 20 years, Tecogen has shipped more than 2,300 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit www.tecogen.com or follow us on Twitter, Facebook, and LinkedIn.

Tecogen, InVerde, Ilios, Tecochill, Ultera, and e⁺, are registered trademarks of Tecogen Inc.

(VRML) Announces Publication of First OVA1® Clinical Utility Study

Nearly all of the patients who had primary ovarian malignancies were appropriately referred to gynecologic oncologists, highlighting the clinical utility of OVA1

AUSTIN, Texas, April 19, 2016  — Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the publication of the first clinical utility data demonstrating that identification of high-risk patients using OVA1 prior to surgery resulted in referral of nearly all patients who had primary ovarian malignancies to gynecologic oncologists.  The study, titled “The clinical utility of an elevated-risk multivariate index assay score measured by pre-surgical involvement of gynecologic oncologists in the management of ovarian cancer,” to be published in the peer-reviewed journal Current Medical Research & Opinion (CMRO), is now available online as a pre-print (DOI: 10.1080/03007995.2016.1176014).

Dr. Ramez Eskander, first author and faculty member at UC Irvine’s Division of Gynecologic Oncology in Orange, California, stated, “This study documents the first peer-reviewed evidence on how OVA1 results affect real-world patient care. Approximately 80% of patients with a high-risk OVA1 result were referred to or consulted with a gynecologic oncologist, providing an opportunity for critical pre-surgical input to patient care. Even more important, 100% specialist involvement was found in the 65 primary ovarian cancer cases, with 94% of these surgeries being performed by a gynecologic oncologist.”

Vermillion’s Chief Medical Officer and co-author of the study, Dr. Judith Wolf, added, “An important opportunity to improve survival is lost when initial ovarian cancer surgery and treatment is not performed by a trained specialist. Unfortunately, many women fail to receive this care today, in part due to less sensitive and more subjective methods commonly used to assess ovarian cancer risk prior to surgery. Our clinical utility study of high-risk OVA1 results represents an important step in providing women with highly effective access to specialist care for ovarian cancer.”

The study surveyed physicians with frequent OVA1 use, and identified 122 patients who underwent surgery for a pelvic mass after a high-risk OVA1 score was reported. Of these, 65 had a primary ovarian malignancy, while the remainder were benign or had a metastatic cancer of non-ovarian origin. Pre-surgical involvement of a gynecologic oncologist was documented, including referral, consultation or availability on stand-by; and the specialty of the surgeon who performed the adnexal surgery was also recorded. Of the 4 patients whose surgery was not performed by a gynecologic oncologist, 2 required re-operation for complete staging by a gynecologic oncologist. In comparison, none of the 61 ovarian cancers that were operated on by a gynecologic oncologist required restaging. According to the National Academy of Medicine’s 2016 report, Ovarian Cancers: Evolving Paradigms in Research and Care, re-operations are common after non-specialists operate on ovarian cancer, and may result in delayed treatment, higher costs and inferior outcomes compared with ‘first time right’ surgery by a gynecologic oncologist.

Clinical utility of low-risk OVA1 results may be the subject of a future publication.

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer serious diseases.  The company’s initial in vitro diagnostic test, OVA1^®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

About OVA1^® and Overa™

• OVA1 is a proprietary FDA-cleared blood test to help physicians assess the risk of ovarian cancer prior to surgery and as a result provide more effective referral of high risk patients to a specialist (gynecologic oncologist) for surgical treatment
• The OvaCalc^® proprietary algorithm combines five biomarker results into a single numerical “risk score” that stratifies patients into “higher risk” and “lower risk” when combined with clinical assessment
• In two pivotal clinical trials, OVA1 plus clinical impression detected 96% of all malignancies vs. 75% for clinical impression alone (CI). As a result, false negatives were reduced from 25% for CI, to 4% with OVA1 plus CI, a reduction of 83%
• In a study focused on early-stage cancer detection, 31% of cases were missed by clinical impression alone. This was reduced to 5% when OVA1 was added to clinical impression, a reduction of 85%
• Overa, cleared by FDA on March 18, 2016, measures the levels of five proteins found in the blood and then uses a second-generation OvaCalc^® algorithm to stratify risk. A woman’s risk of cancer is measured by using a 0-10 scale with a single cut-off point of 5 eliminating the ambiguity in determining menopausal status. A high Overa score is not a diagnosis of cancer, rather it indicates an increased risk of malignancy when used as intended.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant a number of risks and uncertainties, including with respect to future publications.  Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion’s expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to factors that are described in Vermillion’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

(PLG) Reports 13% Increase in F Zone Grade, 89% Increase in Indicated Resources

Waterberg Pre-Feasibility Study Continues for a Decline Tunnel Access and a Fully Mechanized Mine Plan

R. Michael Jones, President & CEO
or Kris Begic, VP, Corporate Development
Platinum Group Metals Ltd., Vancouver
(604) 899-5450 / Toll Free: (866) 899-5450
www.platinumgroupmetals.net

(EXPI) MissionIR Exclusive Audio Interview With CEO Glenn Sanford

(AMDA) Signs Exclusive Chinese Silicon Nitride Distribution Agreement

10-Year Exclusive Agreement to Represent Significant Global Sales Expansion and Minimum Purchase Requirements

(HRTX) Provides Update on FDA Review of SUSTOL® NDA

Heron Therapeutics, Inc. (NASDAQ: HRTX), announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL^® (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.

SUSTOL is a long-acting formulation of the FDA-approved 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonist granisetron being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). SUSTOL is formulated utilizing Heron’s proprietary Biochronomer^® drug delivery technology, and has been shown to maintain therapeutic drug levels of granisetron for at least five days with a single subcutaneous injection.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit www.herontx.com.

Forward-Looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: whether the U.S. Food and Drug Administration (FDA) completes its review within any anticipated time period, whether the FDA approves the SUSTOL NDA as submitted or supports as broad of a labeled indication for SUSTOL as requested, and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations
jcapuzelo@herontx.com
or
Corporate Contact:
Barry D. Quart, 650-366-2626
Pharm D., Chief Executive Officer

(IPWR) Reports Semiconductor Fabricator Successfully Tested Its B-TRAN Technology

Third Party Testing of First B-TRAN Semiconductor Structures Validate Key Performance Characteristics